- On Sept. 2, the U.S. Food and Drug Administration (FDA) approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting. Read more.
- On Aug. 27, the FDA approved Repatha (evolocumab) injection for some patients who are unable to control their low-density lipoprotein (LDL) cholesterol with current treatment options. Read more.
FDA approves new drugs
Share